Der Miner von Kryptowährungen setzt auf ökologische Effizienz und baut seine Rechenzentren direkt in bereits ...
Rösch market position strengthened
Berlin (ots) -
- New order for INJEX(tm)
- Inhalativ insulin from Pfizer delayed
- Powderject disposes its needle-free powder injection
The Berlin company Rösch AG Medizintechnik (SIN 529140) announces
an additional order for the needle-free injection system INJEX(tm)
from Saudi Arabia, within the context of the co-operation with
Burjuman Pharmaceutical Consultants (BPC), Dubai, UAE. The order
volume comprises approximately DEM 750,000. August 2001 has been
advised for full delivery.
This order comes under the first quarter of the 2001/2002
financial year of the company, which commences August 1.
For the first quarter Rösch AG has scheduled the start of sales
activities for INJEX(tm) in France, where approval by health
insurance companies has been granted and where it is being
reimbursed. In Germany a decision on approval by the health insurance
companies is expected and commencement of advertising activities is
scheduled for the end of August/beginning of September 2001.
While Rösch AG is thus actively pushing its leading role on the
market for needle-free injection systems, announcements by other
companies are strengthening Rösch AG's market position.
On July 17, 2001 in the context of publishing its results for the
second quarter, Pfizer Inc. announced a possible delay in FDA
approval of its inhalational insulin.
Several days earlier Powderject Pharmaceuticals had announced that
it will most likely dispose of its business area of needle-free
powder injections. This method of injection requires the
reformulation of liquid medications into powder, thus requiring a
lengthy approval procedure. The time advantage of the Rösch systems
was tremendous. The only important competitor to remain in
sub-segments is now Weston Medical.
ots Originaltext: Rösch AG Medizintechnik
Rösch AG Medizintechnik
Buckower Damm 114
Tel. +49 30 667915 37
Fax +49 30 667915 66